TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Benzinga Logo Benzinga By Globe Newswire
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Royalty Pharma has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in sales-based milestones. Following the transaction, Royalty Pharma will own 100% of the tiered 8% to 16% royalty on worldwide net sales of Evrysdi, an FDA-approved spinal muscular atrophy treatment that generated approximately $1.9 billion in sales in 2024 with projected growth to $2.9 billion by 2030.

Insights
OILU   neutral

Proposed a modular approach to AI agents, focusing on specialized, discrete task performance


RPRX   positive

Acquisition of full royalty ownership on a high-growth commercial product (Evrysdi) with strong sales trajectory ($1.9B in 2024, projected $2.9B by 2030) and 18% YoY growth. This consolidates Royalty Pharma's position in a profitable revenue stream with tiered royalty rates up to 16%.